Lilly backs OrsoBio’s $60M Series A for PhII trials in obesity and NASHnews2023-11-07T13:00:18+00:00November 7th, 2023|Endpoints News|
Gilead, Arcus’ PhII gastroesophageal cancer data argue for TIGIT antibody drug class potentialnews2023-11-07T12:27:45+00:00November 7th, 2023|Endpoints News|
Ventyx Biosciences’ stock drops over 70% after axing psoriasis drug programnews2023-11-07T12:14:31+00:00November 7th, 2023|Endpoints News|
AppliedVR is betting a new study could strengthen the case for insurance coverage of its VR chronic pain treatmentnews2023-11-07T12:00:21+00:00November 7th, 2023|Endpoints News|
Novartis licenses HDAC6 inhibitor from Korea’s Chong Kun Dang Pharm for $80M upfrontnews2023-11-07T12:00:13+00:00November 7th, 2023|Endpoints News|
Exclusive: With backing of Ravens owner, Blackbird launches with $100M to boost Baltimore’s biotech scenenews2023-11-07T11:00:08+00:00November 7th, 2023|Endpoints News|
Dutch-US biotech raises $61M to test ex-Mitsubishi Tanabe drug for schizophrenianews2023-11-07T10:00:59+00:00November 7th, 2023|Endpoints News|
Vertex discontinues a PhII rare disease drug, sets early 2024 timeline for pivotal non-opioid pain pill readoutnews2023-11-07T09:34:44+00:00November 7th, 2023|Endpoints News|
‘Pull every lever’: Marks doubles down on urgency to improve gene therapy manufacturingnews2023-11-06T20:39:55+00:00November 6th, 2023|Endpoints News|
Bristol Myers’ new effort spotlights psoriasis patients and physicians from around the worldnews2023-11-06T20:20:27+00:00November 6th, 2023|Endpoints News|
